Skip to main content
Clinical Trials/NCT02908633
NCT02908633UnknownNot Applicable

Comparison of Safety and Efficacy of Three Variants of Canaloplasty: Ab-externo, Ab-interno and Minicanaloplasty Combined With Phacoemulsification to Treat Glaucoma and Cataract. A Randomised, Prospective Study.

Military Institute od Medicine National Research Institute1 site in 1 country90 target enrollmentStarted: February 1, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
90
Locations
1
Primary Endpoint
mean IOP

Study Overview

Brief Summary

It is a comparative study of Safety and Efficacy of Three Variants of Canaloplasty: ab-externo, ab-interno and minicanaloplasty. Combined With Phacoemulsification to Treat Glaucoma and Cataract. It is a Randomised, Prospective Study.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Investigator)

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •co-existing glaucoma and cataract
  • •glaucoma types: primary open angle glaucoma,
  • •eye with characteristic glaucoma changes (biomicroscopic,visual field)
  • •IOP over 21 mmHg after washout
  • •patients not tolerating antiglaucoma medications,
  • •patients with poor compliance
  • •progression in visual field

Exclusion Criteria

  • •previous surgical glaucoma procedure
  • •previous cataract surgery
  • •BCVA under 0,004
  • •closed angle glaucoma secondary glaucoma (pseudoexfoliative, pigmentary)
  • •poorly controlled diabetes mellitus
  • •advanced AMD
  • •active inflammatory disease
  • •pregnancy
  • •mental disease or emotional instability general steroid therapy

Arms & Interventions

canaloplasty ab externo and phacoemulsification

Active Comparator

As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation

Intervention: canaloplasty and phacoemulsification (Procedure)

canaloplasty ab interno and phacoemulsification

Active Comparator

This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.

Intervention: canaloplasty and phacoemulsification (Procedure)

minicanaloplasty and phacoemulsification

Active Comparator

The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation

Intervention: canaloplasty and phacoemulsification (Procedure)

Outcomes

Primary Outcomes

mean IOP

Time Frame: change form baseline at 24 months

Number of antiglaucoma drugs

Time Frame: change from baseline at 24 months

intraoperative complications

Time Frame: at the day of surgery

Secondary Outcomes

  • Early and Late postsurgical complications(within 24 months)
  • Best-Corrected Visual Acuity(change from baseline at 24 months)
  • Visual Field changes(change from baseline at 24 months)
  • % IOP reduction(change at 24 months from baseline)

Investigators

Sponsor
Military Institute od Medicine National Research Institute
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Marek Rekas

MD, PhD Professor of Ophthalmology

Military Institute od Medicine National Research Institute

Study Sites (1)

Loading locations...

Similar Trials